Flow Traders U.S. LLC Has $2.28 Million Stock Position in Novo Nordisk A/S $NVO

Flow Traders U.S. LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 535.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,121 shares of the company’s stock after purchasing an additional 34,654 shares during the quarter. Flow Traders U.S. LLC’s holdings in Novo Nordisk A/S were worth $2,282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. True Wealth Design LLC grew its position in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S during the third quarter worth $30,000. Allianz SE grew its holdings in Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares during the period. Finally, Financial Life Planners bought a new stake in Novo Nordisk A/S in the third quarter valued at $33,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NVO has been the topic of several research reports. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective on the stock in a report on Tuesday, March 3rd. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research report on Tuesday, March 10th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. CICC Research initiated coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S Trading Up 1.6%

NYSE:NVO opened at $38.57 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57. The company has a market cap of $172.22 billion, a PE ratio of 11.12 and a beta of 0.74. The firm has a 50-day moving average of $49.81 and a 200-day moving average of $51.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.